

Poly Medicure Limited

Regd. Office : 232-B, 3rd Floor, Okhla Industrial Estate,
Phase-III, New Delhi - 110020 (INDIA)
T: +91-11-33550700, 47317000, F: +91-11-26321894, 26321839
E: info@polymedicure.com W: polymedicure.com
CIN: L 40300DL1995PLC066923



February 18, 2021

National Stock Exchange of India Limited Exchange Plaza, C-1, Block – G Bandra Kurla Complex, Bandra (East) Mumbai 400 051 Maharashtra, India Scrip code: POLYMED	BSE Limited Corporate Relationship Department PJ Towers, 25 th Floor, Dalal Street Mumbai 400 001 Maharashtra, India Scrip Code: 531768
--	---

Re: Qualified institutions placement of equity shares of face value of ₹ 5 each (the “Equity Shares”) by Poly Medicure Limited (“Company”) to qualified institutional buyers (the “QIP”) under the provisions of Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 and Companies Act, 2013 (including the rules made thereunder)

Sub: Outcome of the meeting of the QIP Committee

Dear Sir,

We wish to inform you that in respect of the QIP, the QIP Committee of the Company has, at its meeting held today approved and adopted the placement document dated February 18, 2021 in connection with the QIP.


The QIP Committee’s meeting commenced at 10.00 p.m. and the meeting was concluded at 10.30 p.m.

The QIP was opened on February 15, 2021 and closed today i.e. on February 18, 2021 and the same was intimated to you pursuant to our letters dated February 15, 2021 and February 18, 2021, respectively.

We request you to take the above on record pursuant to compliance under Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

Thank you,

For Poly Medicure Limited


Avinash Chandra
Company Secretary



CERTIFIED TRUE COPY OF THE RESOLUTION PASSED IN THE MEETING OF THE QIP COMMITTEE OF POLY MEDICURE LIMITED HELD ON THURSDAY THE 18TH DAY OF FEBRUARY, 2021 AT 10.00 P.M. AT 232-B, 3RD FLOOR, OKHLA INDUSTRIAL ESTATE, PHASE-III, NEW DELHI - 110020.

1 Approval of Placement Document



“RESOLVED THAT the placement document dated February 18, 2021 (“Placement Document”) circulated to this QIP Committee and initiated by Mr. Himanshu Baid, Managing Director placed before this meeting, in respect of the qualified institutions placement of equity shares of ₹ 5 each of the Company for an aggregate amount not exceeding ₹ 400 crore, to qualified institutional buyers (“QIBs”), in terms of Chapter VI of the Securities and Exchange Board of India (Issue of Capital and Disclosure) Regulations, 2018, as amended (“SEBI ICDR Regulations”), and Sections 42 and 62 of the Companies Act, 2013 and the rules and regulations thereunder, each as amended, (the “Issue”), be and is hereby finalized and approved for filing with the BSE Limited and the National Stock Exchange of India Limited (together the “Stock Exchanges”), and any other statutory and regulatory authority, as may be required under applicable laws, subject to such modifications, additions, omissions, corrections, etc., as may be required to be undertaken prior to such filing, and as may be approved by any of Mr. Himanshu Baid, Managing Director and Mr. Rishi Baid, Joint Managing Director acting either severally or jointly, as they, in their absolute discretion, may deem necessary, expedient or appropriate.

RESOLVED FURTHER THAT Mr. Himanshu Baid, Managing Director and Mr. Rishi Baid, Joint Managing Director be and are hereby severally authorised to sign the Placement Document on behalf of the Company, make such confirmations, declaration and any changes on behalf of the Company as may be required in relation to the Placement Document, prior to filing of the Placement Document with the Stock Exchanges, and for filing the Placement Document along with other documents as required under the Companies Act, 2013, as amended (“Companies Act”), intimating the Stock Exchanges in relation to the above and making regulatory filings, as required, settle or give instructions and directions for settling any questions, difficulties or doubts that may arise in this regard and to give effect to such changes, alterations, updates, additions, omissions, revisions, variations, amendments, modifications or corrections as may be deemed fit and proper in the best interest of the Company in accordance with the applicable laws and regulations and in consultation with the legal advisors and the book running lead managers appointed for the Issue.

RESOLVED FURTHER THAT Mr. Himanshu Baid, Managing Director and Mr. Rishi Baid, Joint Managing Director, as authorised representatives of the Company, be and are hereby authorized, severally or jointly, to take such action or to do all deeds, matters and things, including finalizing and executing/ signing such documentation and undertakings as may be necessary, proper, desirous, appropriate or expedient to give effect to the above resolutions, issuance of confirmation of allocation notes to investors identified for allotment and the filing of necessary returns, for the issue and allotment of the equity shares of the Company.

RESOLVED FURTHER THAT a copy of the above resolution, certified to be true by any of the Directors of the Company or the Company Secretary of the Company, be forwarded to the authorities concerned for necessary action.”

For Poly Medicure Limited

Himanshu Baid
Managing Director